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Retinal Detachment with Macular Hole Following Combined 
Photodynamic Therapy and Intravitreal Bevacizumab Injection
Eun Jee Chung, MD, Hyoung Jun Koh, MD
The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
Purpose: To report a case of retinal detachment with a macular hole following photodynamic therapy (PDT) 
using verteporfin and intravtreal bevacizumab injection in the treatment of myopic choroidal neovasclarization 
(CNV). 
Methods: A 58 -year-old woman was diagnosed with myopic CNV and treated with a combination of PDT 
with verteporfin and intravitreal bevacizumab injection that same day. She received the second injection of 
intravitreal bevacizumab four weeks after the initial treatment. 
Results:  The patient developed a sudden decline in vision one week after the second injection; and was 
subsequently diagnosed with retinal detachment associated with a macular hole. She underwent standard 
three-port pars plana vitrectomy with internal limiting membrane peeling, fluid-air exchange and silicone oil 
injection. The retina was still firmly attached at the patient‘s final follow-up visit.
Conclusions: PDT and intravitreal bevacizumab injection used for the treatment of myopic CNV can be 
associated with retinal detachment with a macular hole. Patients need to be informed about this potential 
complication, and a higher index of suspicion may be warranted in patients who report sudden vision loss 
after the treatment. 
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Recently, intravitreal bevacizumab (Avastin) injection has 
gained popularity as a potential treatment for choroidal 
neovascularization (CNV) associated with age related 
macular degeneration and pathologic myopia. The injection is 
utilized, either as a sole treatment or combined with 
photodynamic therapy (PDT) using verteporfin.
1,2 Although 
there is no definitive information on longterm safety for 
either intravitreal bevacizumab or combined treatment, these 
therapies are considered safe and have no known serious 
ocular or systemic adverse events.
1-3  
Herein, we present a patient with myopic CNV, who 
developed retinal detachment with a macular hole following 
combined PDT and intravitreal bevacizumab injection.
Case Report
A 58-year-old woman was diagnosed with CNV secondary 
to pathologic myopia in her right eye (right eye = -17 D, left 
eye = -15 D) (Fig. 1). The best corrected visual acuity in the 
affected eye as measured with a Snellen chart was 20/200. 
After an informed discussion of available therapies, the 
patient received combined PDT and 1.25 mg intravitreal 
bevacizumab injection. Four weeks after the initial treatment, 
the patient received a second intravitreal bevacizumab 
injection. Both treatments were uneventful.
A week after receiving the second injection, the patient 
presented with worsening vision in her right eye. Her visual 
acuity was counting fingers at 1 m. Examination revealed 
retinal detachment involving the posterior pole with a 
macular hole. Ocular coherence tomography (OCT) 
confirmed the presence of a macular hole (Fig. 2). 
The patient underwent standard three-port pars plana 
vitrectomy with internal limiting membrane peeling, fluid-air 
exchange and silicone oil injection. During the operation, 
peripheral fundus examination was performed with scleral 
indentation, and no additional peripheral hole was observed. 
On follow-up one week later, the macula had flattened and 
visual acuity was 20/400. 
Discussion
The development of retinal detachment with a macular 
hole may occur as a spontaneous process in highly myopic 
eyes.
4  However, the retinal detachment with a macular hole Kor J Ophthalmol Vol.21, No.3, 2007
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Fig. 1. (A) Fundus photography of the right eye before treatment demonstrates a juxtafoveal grayish subretinal membrane with 
subretinal fluid and hemorrhage. (B) Late phase of the fluorescein angiography shows diffuse leakage from a juxtafoveal choroidal
neovascularization.
Fig. 2. (A) Fundus photography 5 weeks after initial combined treatment of PDT and intravitreal bevacizumab, and 1 week after
the second intravitreal bevacizumab injection; demonstrating serous retinal detachment of the posterior pole with a macular hole. (B)
OCT confirms the presence of a macular hole.
in our patient occurred shortly after PDT and repeated 
injections of intravitreal bevacizumab. Therefore, the time 
course suggests the treatment had a potentially causal role.
Several possible mechanisms may have induced the 
development of retinal detachment with a macular hole. The 
intravitreal injection may have induced vitreous incarceration 
at the needle insertion site, causing vitreoretinal traction 
leading to development of a macular hole and subsequent 
retinal detachment.
5-7  We performed a combined treatment, 
and there has been a report of macular hole development 
several weeks after PDT treatment using verteporfin. Thus, 
PDT may have induced the development of the macular 
hole.
8 Lastly, bevacizumab itself may have caused the 
macular hole by modulating the permeability and activity of 
the CNV and inducing contraction of the vascular membrane, 
leading to exacerbation of tangential traction on the overlying 
retina.
9-11 The short duration in the onset of retinal 
detachment with a macular hole after the second injection of 
intravitreal bevacizumab also suggests a possible causal role 
of the drug.
In conclusion, PDT and intravitreal bevacizumab injection 
in the treatment of myopic CNV can be associated with 
retinal detachment with a macular hole. Patients need to be 
informed about this potential complication, and a higher 
index of suspicion may be warranted in patients who report 
sudden vision loss after the treatment.
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